This was the stock's fourth consecutive day of losses.

At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

Bailard Inc. increased its stake in Regeneron Pharmaceuticals by 10.1% in Q4, raising its holdings to 13,422 shares.

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

In a much-anticipated decision, the First Circuit unanimously ruled the government and relators must prove that a violation ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Maya Ajmera, President & CEO of Society for Science and Executive Publisher of Science News, chatted with Walter “Ted” Carter Jr., President of The Ohio ...

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

President Trump on Tuesday said workers who do not respond to an email from the Office of Personnel Management prompted by ...